Jazz Pharmaceuticals JAZZ Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's retained earnings?
- Jazz Pharmaceuticals (JAZZ) reported retained earnings of $939.2M in Q1 2026.
- How has Jazz Pharmaceuticals's retained earnings changed year-over-year?
- Jazz Pharmaceuticals's retained earnings decreased by 9.2% year-over-year, from $1.03B to $939.2M.
- What is the long-term trend for Jazz Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's retained earnings has grown at a -11.0% compound annual growth rate (CAGR), from $1.16B to $646.1M.
- What does retained earnings mean?
- The total profit the company has kept and reinvested in the business since it started.
- How do you interpret retained earnings?
- Consistent growth indicates strong profitability and effective capital reinvestment, while a decline may signal losses or heavy dividend payouts.
- How does retained earnings compare across companies?
- Standard across all companies; a key indicator of long-term financial health and maturity.